Head of the French Group of Immunotherapy, Institute of Gustave Roussy, Paris, France
Dr Bernard Escudier trained in Paris. He received his MD in 1981 as a cardiologist, and moved to Gustave Roussy Institute in 1983, initially in the Intensive Care Unit, and then took the lead of the Immunotherapy Unit, mainly in charge of developing programs in renal cell carcinoma and in melanoma. His largest fields of interest are renal cell carcinoma, immunotherapy (cytokines, vaccines), and development of new strategies (antiangiogenic drugs, gene therapy). He has been largely involved in the development of new targeted therapies for RCC, and has been the PI of many trials in the field of RCC, from phase I to phase III.
Dr Escudier has been head of the French Group of Immunotherapy since 1992, and is the chairman of the GU tumor board at Gustave Roussy Institute in Villejuif, France. He is a member of ASCO, AACR, ESMO, and has been the chair of the GU Group of ESMO from 2008 to 2010, and is currently the ESMO faculty coordinator for the GU group. He has published more than 290 papers in peer reviewed journals, mainly in the field of Renal Cancer.